{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:27:28Z","timestamp":1793755648942,"version":"4.6.1"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T00:00:00Z","timestamp":1602115200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.jgar.2020.09.029","type":"journal-article","created":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T01:29:17Z","timestamp":1603157357000},"page":"284-285","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Attainment of therapeutic posaconazole serum levels during co-administration with rifampicin"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7671-6193","authenticated-orcid":false,"given":"Nicholas","family":"Power","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1800-0677","authenticated-orcid":false,"given":"Fiona","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5626-2251","authenticated-orcid":false,"given":"David W.","family":"Denning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Bazaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2020.09.029_bib0005","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2165\/00003088-200342090-00003","article-title":"Pharmacokinetic interactions with rifampicin: clinical relevance","volume":"42","author":"Niemi","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jgar.2020.09.029_bib0010","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-2125.2010.03680.x","article-title":"Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview","volume":"70","author":"Lipp","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jgar.2020.09.029_bib0015","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1086\/650740","article-title":"Rifampin and posaconazole coadministration leads to decreased serum posaconazole concentrations","volume":"50","author":"Hohmann","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2020.09.029_bib0020","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1185\/030079906X167507","article-title":"Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men","volume":"23","author":"Krishna","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jgar.2020.09.029_bib0025","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/jac\/dky539","article-title":"Therapeutic drug monitoring and adverse events of delayed-release posaconazole tablets in patients with chronic pulmonary aspergillosis","volume":"74","author":"Kosmidis","year":"2019","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716520302605?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716520302605?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:55:57Z","timestamp":1761990957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716520302605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":5,"alternative-id":["S2213716520302605"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2020.09.029","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Attainment of therapeutic posaconazole serum levels during co-administration with rifampicin","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2020.09.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}